Related Experiment Video
Updated: Jun 15, 2025
Deficient Pms2, ERCC1, Ku86, CcOI in Field Defects During Progression to Colon Cancer
Published on: July 28, 2010
Immune profiling of premalignant lesions in patients with Peutz-Jeghers syndrome
Zhongyue Liu1,2, Boda Wu3, Xiaoliu Shi4,5
1Hunan Key Laboratory of Tumor Models and Individualized Medicine, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
Background:
Peutz-Jeghers syndrome (PJS), is a rare autosomal dominant hereditary disease characterized by an elevated risk of various cancers. Serine/Threonine Kinase 11 (STK11) gene is a major tumor suppressor crucial for immune evasion with and beyond tumorigenic cells. It has garnered increasing attention in the realm of oncology treatment, particularly in the context of immunotherapy development.
Objective:
This study aimed to assess the suitability of polyps obtained from individuals with PJS, resulting from germline STK11 deficiency, for immunotherapy. Additionally, we seek to identify potential shared mechanisms related to immune evasion between PJS polyps and cancers. To achieve this, we examined PJS polyps alongside familial adenomatous polyposis (FAP) and sporadic polyps.
Methods:
Polyps were compared among themselves and with either the paracancerous tissues or colon cancers. Pathological and gene expression profiling approaches were employed to characterize infiltrating immune cells and assess the expression of immune checkpoint genes.
Results:
Our findings revealed that PJS polyps exhibited a closer resemblance to cancer tissues than other polyps in terms of their immune microenvironment. Notably, PJS polyps displayed heightened expression of the immune checkpoint gene CD80 and an accumulation of myeloid cells, particularly myeloid-derived suppressor cells (MDSCs).
Conclusion:
The findings suggest an immunobiological foundation for the increased cancer susceptibility in PJS patients, paving the way for potential immune therapy applications in this population. Furthermore, utilizing PJS as a model may facilitate the exploration of immune evasion mechanisms, benefiting both PJS and cancer patients.
Insights
Peutz-Jeghers syndrome (PJS) polyps resemble cancer tissues, showing immune evasion mechanisms. This suggests PJS patients may benefit from immunotherapy, advancing cancer treatment research.
Area of Science:
- Oncology
- Immunology
- Genetics
Background:
- Peutz-Jeghers syndrome (PJS) is a rare genetic disorder linked to increased cancer risk.
- The STK11 gene, a tumor suppressor, plays a key role in immune evasion and is implicated in PJS.
- Understanding PJS may offer insights into broader cancer immunotherapy strategies.
Purpose of the Study:
- To evaluate PJS polyps for immunotherapy suitability.
- To identify shared immune evasion mechanisms between PJS polyps and cancers.
- To compare PJS polyps with other polyp types and cancer tissues.
Main Methods:
- Comparative analysis of PJS, familial adenomatous polyposis (FAP), and sporadic polyps.
- Examination of paracancerous tissues and colon cancers.
- Pathological assessment and gene expression profiling of immune cells and checkpoint genes.
Main Results:
- PJS polyps share immune microenvironment characteristics with cancer tissues.
- Elevated expression of the immune checkpoint gene CD80 was observed in PJS polyps.
- Accumulation of myeloid cells, including myeloid-derived suppressor cells (MDSCs), was noted in PJS polyps.
Conclusions:
- PJS polyps exhibit an immunobiological profile supporting increased cancer susceptibility.
- Findings suggest potential for immunotherapy applications in Peutz-Jeghers syndrome.
- PJS serves as a valuable model for studying immune evasion in both PJS and general cancer patients.
